YCANTH
Total Payments
$1.4M
Transactions
14,545
Doctors
8,179
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $999,700 | 10,814 | 6,439 |
| 2023 | $351,323 | 3,731 | 2,789 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $816,775 | 328 | 60.5% |
| Food and Beverage | $355,212 | 13,955 | 26.3% |
| Consulting Fee | $138,632 | 85 | 10.3% |
| Travel and Lodging | $40,403 | 177 | 3.0% |
Top Doctors Receiving Payments for YCANTH — Page 328
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.4M
- Total Doctors 8,179
- Transactions 14,545
About YCANTH
YCANTH is a drug associated with $1.4M in payments to 8,179 healthcare providers, recorded across 14,545 transactions in the CMS Open Payments database. The primary manufacturer is Verrica Pharmaceuticals Inc..
Payment data is available from 2023 to 2024. In 2024, $999,700 was paid across 10,814 transactions to 6,439 doctors.
The most common payment nature for YCANTH is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($816,775, 60.5% of total).